Headlines Covid-19 Specialties Trending Feeds Videos

CAR T Explodes on the Scene in Heavily Pretreated Multiple Myeloma

posted 2 days

Mashup Score: 1

OncLive - Binod Dhakal, MD, discusses the potential impact of ide-cel, orva-cel, and cilta-cel in multiple myeloma...

Assessing the Advantages of Adjuvant Targeted Therapy in Lung Cancer

posted 12 hours

Mashup Score: 1

OncLive - David Spigel, MD, discusses the future of adjuvant targeted therapy in lung...

Dr. Matsen on the Effects of Decreased Breast Cancer Screening in the COVID-19 Era

posted 3 hours

OncLive - Cindy B. Matsen, MD, discusses the potential effects of the decrease in screening for patients with breast cancer during the coronavirus disease 2019...

Dr. Callander on Selecting a Frontline Treatment Strategy in Multiple Myeloma

posted 1 day

OncLive - Natalie S. Callander, MD, discusses selecting a frontline treatment strategy for patients with multiple...

FDA Issues Complete Response Letter for Oral Paclitaxel Plus Encequidar for Metastatic Breast Cancer

posted 43 mins

OncLive - The FDA has issued a complete response letter to Athenex, Inc. stating that it will not, at this time, approve the new drug application...

  • #ICYMI: @US_FDA has issued a complete response letter to Athenex, Inc. stating that it will not, at this time, approve the new drug application for oral paclitaxel in combination with encequidar for the treatment of patients with metastatic breast cancer https://t.co/2WDygY2D6e

TKI/Immunotherapy Combos Dominate Frontline Metastatic RCC Management

posted 2 days

OncLive - Claud N. Grigg, MD, highlights different frontline combination regimens that are improving outcomes for patients with metastatic renal cell...

Dr. Schmidt on the Utilization of Bispecific Antibodies in Myeloma

posted 21 hours

OncLive - Timothy M. Schmidt, MD, discusses the utilization of bispecific antibodies in...

Immunotherapy Keeps Impressing in Advanced NSCLC, With Improvements on the Horizon

posted 2 days

OncLive - Davey B. Daniel, MD, discusses key immunotherapy trials in advanced non–small cell lung cancer and explains how the results can be extrapolated to clinical...

Dr. Bekaii-Saab Discusses Indicators of Progression in CRC

posted 19 hours

OncLive - Tanios S. Bekaii-Saab, MD, FACP, discusses indicators of progression in colorectal...

Dr. Lin on the Importance of Developing non-BCMA–Targeting Agents in Myeloma

posted 16 hours

OncLive - Yi Lin, MD, PhD, discusses the importance of developing non-BCMA–targeting agents in multiple...